Meyka Pro banner
Genmab A/S

Genmab A/S (GMAB) Stock Overview

Explore Genmab A/S’s financial performance, market position, analyst ratings, and future outlook.

GMAB●NASDAQ
HealthcareBiotechnology
$51.37
$0.37(0.72%)
U.S. Market opens in 3h 51m

Genmab A/S (GMAB)

Meyka AI Score

Z

Key Financials

Market Cap31.7B
P/E Ratio43.34
EPS (TTM)$1.33
ROE0.12%
Fundamental Analysis

AI Price Forecasts

1 Month$60.62
3 Months$39.12
1 Year Target$36.58

GMAB Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Genmab A/S (NASDAQ: GMAB) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Genmab A/S's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of GMAB on the NASDAQ shows an RSI of 58.98, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $36.58 for the NASDAQ listing.

Key metrics behind Genmab A/S's NASDAQ-traded stock include a P/E ratio of 43.34 and a market capitalization of 31.7B. Combined with our AI analysis, these give both institutional and retail investors a clear view of GMAB on the NASDAQ.

Price Performance (NASDAQ: GMAB)

1-Day Change
-0.72%
5-Day Change
-1.89%
1-Month Change
40.47%
3-Month Change
63.91%
6-Month Change
93.48%
Year-to-Date (YTD) Change
66.79%
1-Year Change
69.87%
3-Year Change
59.78%
5-Year Change
24.78%
All-Time (Max) Change
1262.60%

Contact Information

45 70 20 27 28
Carl Jacobsens Vej 30, Copenhagen, CD, 2500

Company Facts

32,440 Employees
IPO DateJun 1, 2009
CountryDK
Actively Trading

Frequently Asked Questions